CADTH Canadian Drug Expert Committee Recommendation: Tapentadol Hydrochloride (Nucynta Extended-Release — Paladin Labs Inc.): Indication: Management of pain severe enough to require daily, continuous, long-term opioid treatment, and: that is opioid responsive; and for which alternative treatment options are inadequate. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018.

Leave a Reply